Research Article TheInfluenceofPersonalisedSarcomaCare(PERSARC) PredictionModellingonClinicalDecisionMakingina Multidisciplinary Setting H.S.FemkeHagenmaier , 1 AnneliesG.K.vanBeeck, 2,3 RickL.Haas , 4,5 VeroniekM.vanPraag, 2 LetivanBodegom-Vos, 6 JosA.vanderHage, 7 StijnKrol, 4 FrankM.Speetjens, 8 ArjenH.G.Cleven, 9 AnaNavas, 10 HermanM.Kroon, 10 RienekeG.Moeri-Schimmel, 4 NicoletteA.C.Leyerzapf, 2 andMichielA.J.vandeSande 2 1 Department of Orthopaedic Surgery, Sint Maartenskliniek, Hengstdal 3, 6574 NA Ubbergen, Netherlands 2 Department of Orthopaedic Surgery, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands 3 Department of Orthopaedic Surgery and Traumatology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium 4 Department of Radiotherapy, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands 5 Department of Radiotherapy, e Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands 6 Department of Biomedical Data Sciences, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands 7 Department of Surgery, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands 8 Department of Clinical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands 9 Department of Pathology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands 10 Department of Radiology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands Correspondence should be addressed to Michiel A. J. van de Sande; m.a.j.van_de_sande@lumc.nl Received 21 September 2020; Revised 27 September 2021; Accepted 29 September 2021; Published 21 October 2021 Academic Editor: Cornelis Verhoef Copyright © 2021 H. S. Femke Hagenmaier et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. With soft-tissue sarcoma of the extremity (ESTS) representing a heterogenous group of tumors, management decisions are often made in multidisciplinary team (MDT) meetings. To optimize outcome, nomograms are more commonly used to guide individualized treatment decision making. Purpose. To evaluate the influence of Personalised Sarcoma Care (PERSARC) on treatment decisions for patients with high-grade ESTS and the ability of the MDT to accurately predict overall survival (OS) and local recurrence (LR) rates. Methods. Two consecutive meetings were organised. During the first meeting, 36 cases were presented to the MDT. OS and LR rates without the use of PERSARC were estimated by consensus and preferred treatment was recorded for each case. During the second meeting, OS/LR rates calculated with PERSARC were presented to the MDT. Differences between estimated OS/LR rates and PERSARC OS/LR rates were calculated. Variations in preferred treatment protocols were noted. Results. e MDT underestimated OS when compared to PERSARC in 48.4% of cases. LR rates were overestimated in 41.9% of cases. With the use of PERSARC, the proposed treatment changed for 24 cases. Conclusion. PERSARC aids the MDT to optimize individualized predicted OS and LR rates, hereby guiding patient-centered care and shared decision making. 1.Introduction Over the last decades, prognostic modelling has found its way into prediction of survival and possible adverse events in sarcoma care. Among the first of those nomograms were the Memorial Sloan Kettering Cancer Center (MSKCC) Sar- coma Nomogram [1], SIN-system [2], and Sarculator [3]. e implementation of these prediction models was mostly Hindawi Sarcoma Volume 2021, Article ID 8851354, 6 pages https://doi.org/10.1155/2021/8851354